The annual international BIO conference in San Diego brought biotech and startup executives face-to-face with two forces reshaping the global drug industry: China's deepening capabilities in drug development and the early competitive signals emerging from artificial intelligence. The week-long gathering at the San Diego convention made clear that U.S.-centric biotech sees both Washington policy and AI adoption as the levers most immediately within reach.
China's Growing Power in Drug Development Takes Center Stage
China's expanding role in the business of developing new drugs became one of the central concerns of BIO 2026, discussed both on stage and in conversations across the exhibition floor. The topic carried urgency because drug development has historically been a domain where U.S. and European companies set the pace; the perception that China is closing that gap — and in some areas pulling ahead — animated much of the week's debate.
The conference drew pavilions representing member countries and states, and executives moved between them with competition in the background, a dynamic made literal when attendees paused to watch World Cup matches on a large screen at a South Korean contract drug manufacturer's booth.
Washington and Pricing Policy on the Agenda
Beyond the competitive threat from China, the industry's roadmap of concerns ran directly through Washington. Executives and speakers addressed how biotech could build a more effective relationship with policymakers and push back on drug pricing policies seen as constraining the sector's growth. Neither the specific policies nor the legislative mechanisms were resolved at the conference; rather, gaining clearer influence over that process was framed as a strategic priority.
AI Strategies Begin Yielding Early Clues
Artificial intelligence occupied the third major strand of the conference, with the industry at a point where initial approaches are beginning to generate information about how the technology can actually deliver a competitive edge — and where it falls short. The emphasis was less on possibility and more on execution: how to move quickly enough on AI that early lessons translate into durable advantage.
The mood at BIO 2026 reflected an industry aware that the competitive map is being redrawn by geography, policy, and technology simultaneously, and that none of those pressures is moving slowly enough to allow a measured response.